Recherche - Archive ouverte HAL Accéder directement au contenu

Filtrer vos résultats

5 Résultats
authFullName_s : Michel Ducreux

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)

Franck Bonnetain , Bert Bonsing , Thierry Conroy , Adelaide Dousseau , Bengt Glimelius et al.
European Journal of Cancer, 2014, 50 (17), pp.2983 - 2993. ⟨10.1016/j.ejca.2014.07.011⟩
Article dans une revue hal-01802621v1

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Thomas T. Aparicio , Michel Ducreux , Roger Faroux , Emilie Barbier , Sylvain Manfredi et al.
European Journal of Cancer, 2018, 98, pp.1-9. ⟨10.1016/j.ejca.2018.03.031⟩
Article dans une revue hal-01983308v1

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects

Simon Pernot , Cecile Badoual , Magali Terme , Florence Castan , Aurelie Cazes et al.
European Journal of Cancer, 2017, 79 (8), pp.15-22. ⟨10.1016/j.ejca.2017.03.036⟩
Article dans une revue hal-01579145v1
Image document

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)

David Tougeron , Pierre Michel , Astrid Lièvre , Michel Ducreux , Sébastien Gaujoux et al.
Digestive and Liver Disease, 2021, 53 (3), pp.306-308. ⟨10.1016/j.dld.2020.11.029⟩
Article dans une revue hal-03102287v1

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

Come Lepage , Laetitia Dahan , Nadia Bouarioua , Christos Toumpanakis , Jean-Louis Legoux et al.
Digestive and Liver Disease, 2017, 49 (5), pp.568 - 571. ⟨10.1016/j.dld.2017.02.004⟩
Article dans une revue hal-01599909v1